Upneeq®
Oxymetazoline hydrochloride 0.1% · ophthalmic solution
Aesthetics/Presbyopia
Approved uses
Acquired blepharoptosis
1 drop into one or both ptotic eyes once daily
Lid elevation is measurable at 5 minutes, peaks near 2 hours, and persists through 8 hours.
OFF-LABELNot in the FDA label for this product
Ptosis of ocular myasthenia gravis
1 drop in the ptotic eye once daily, the labeled frequency
Case report
Single case report, one 68-year-old patient: one drop raised MRD1 by 2.0 mm and gained 15 points on a superior 36-point field screening within 2 hours, with the effect lasting at least 7 hours. The untreated contralateral lid fell, which the authors suggest may be specific to myasthenia. N of 1, no controlled data.
Cosmetic eyelid elevation and conjunctival redness in patients without severe ptosis
1 drop in each eye once daily, the labeled frequency
RCT · n=114 · single dose
Randomized double-masked single-center trial, N=114 (57 treated, 57 control), mean ages 36 and 31: two hours after one drop, MRD1 changed 0.9 mm versus -0.3 mm with placebo (p<0.001) and redness scores fell 2.6 versus 0.5 (p=0.002), with better patient-perceived appearance (p=0.002). Adverse events were all mild and did not differ between groups; the trial measured a single instillation, not chronic use.
Contraindications
None.
0.1% (equivalent to 0.09% oxymetazoline base), 30 single patient-use containers of 0.3 mL
Alpha adrenoceptor agonist acting on a subset of adrenoreceptors in Müller's muscle of the eyelid. Marginal reflex distance 1 reaches its maximum increase about 2 hours after dosing and the increase continues through 8 hours.
Warnings & Precautions
- Ptosis as presenting sign of serious neurologic disease: Ptosis may be associated with neurologic or orbital diseases such as stroke and/or cerebral aneurysm, Horner syndrome, myasthenia gravis, external ophthalmoplegia, orbital infection and orbital masses. Consider these conditions when ptosis comes with decreased levator muscle function and/or other neurologic signs.
- Potential impacts on cardiovascular disease: Alpha-adrenergic agonists may impact blood pressure. Use with caution in severe or unstable cardiovascular disease, orthostatic hypotension, and uncontrolled hypertension or hypotension. Advise patients with cardiovascular disease, orthostatic hypotension, and/or uncontrolled hypertension/hypotension to seek immediate medical care if their condition worsens.
- Potentiation of vascular insufficiency: Use with caution in cerebral or coronary insufficiency or Sjögren's syndrome, and advise patients to seek immediate medical care if signs and symptoms of potentiation of vascular insufficiency develop.
- Risk of angle closure glaucoma: Upneeq may increase the risk of angle closure glaucoma in patients with untreated narrow-angle glaucoma. Advise patients to seek immediate medical care if pain, redness, blurred vision and photophobia occur, the signs and symptoms of acute angle closure.
- Risk of contamination: Patients should not touch the tip of the single patient-use container to the eye or to any surface, to avoid eye injury or contamination of this non-preserved solution.
- Blood pressure impact: Alpha-adrenergic agonists, as a class, may impact blood pressure. Caution is advised with drugs such as beta-blockers, anti-hypertensives and/or cardiac glycosides, and in patients receiving alpha adrenergic receptor antagonists, such as in the treatment of cardiovascular disease or benign prostatic hypertrophy.
- Monoamine oxidase inhibitors: Caution is advised in patients taking MAO inhibitors, which can affect the metabolism and uptake of circulating amines.
- Serious adverse events requiring hospitalization: Accidental oral ingestion of imidazoline derivatives such as oxymetazoline by children has resulted in serious adverse events requiring hospitalization, including nausea, vomiting, lethargy, tachycardia, decreased respiration, bradycardia, hypotension, hypertension, sedation, somnolence, mydriasis, stupor, hypothermia, drooling and coma. Keep out of reach of children.
Common Side Effects
Adverse reactions that occurred in 1-5% of subjects treated with Upneeq were punctate keratitis, conjunctival hyperemia, dry eye, blurred vision, instillation site pain, eye irritation and headache.
Pregnancy: No human data. No adverse developmental effects in rats or rabbits at up to 7 and 278 times the maximum recommended human ophthalmic dose respectively; maternal toxicity with delayed skeletal ossification occurred at the highest rabbit dose.
Lactation: No human data on milk levels or milk production; oxymetazoline was detected in the milk of lactating rats.
Safety and effectiveness not established under 13 years of age.